Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. Issue 12 (March 2019)

• Record Type: Journal Article
• Authors: Zhang, Jian-Qi; Yang, Guo-Hong; Zhou, Xin; Liu, Jun-Xiang; Shi, Rui; Dong, Yan; Chen, Shao-Bo; Li, Yu-Ming
• Other Names: Baltatu. Ovidiu Constantin section editor.
• Is Part Of: Medicine. Volume 98:Issue 12(2019)
• Publication Date: 2019-03
• Subjects: allisartan isoproxil -- blood pressure -- cardiovascular disease -- essential hypertension -- target organ; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014907
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Evidence has shown that angiotensin II type 1 receptor antagonists have lower blood pressure and have target organ protective effects, but this is not the case for the drug allisartan isoproxil. The aim of this study was to evaluate the effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. In total, 80 essential hypertensive participants were randomly divided into an allisartan group and a nifedipine group (n = 40 per group), and their blood pressure was measured once per month for 6 months. A 2-dimensional echocardiogram was performed at baseline and at the end of the study. The serum levels of renal injury indexes, endothelial function markers, inflammatory factors, blood biochemical assays and urinary measurements were determined at baseline and at 6 months. At the end of the study, both systolic and diastolic blood pressure were significantly decreased in the allisartan group compared with baseline and showed the same antihypertensive effect as the nifedipine group. Meanwhile, the left ventricular remodeling, 24-hours levels of urinary microalbumin, endothelial dysfunction, and arterial stiffness were all significantly improved compared with that of the baseline and the nifedipine group (all P < .05). The present study showed that allisartan isoproxil had favorable blood pressure lowering and heart, renal, and endothelial protective effects in patients with mild to moderate essential hypertension.